- Home Page
- EMVDA
- EURHAVAC
- Malaria - The Disease
- Press Releases
- EMVI Statutes
- Board Members and Scientific Advisory Committee Members
- Memoranda of Understanding and Intent
- EMVI Strategy
- Project Portfolio
- Annual Reports
- The Donors
- Mid-Term Review 2005
- Directives - Guidelines - Regulations
- Meeting Reports
- Procedures
- Calls
- Vacancies
- Home Page
- EMVDA
- EURHAVAC
- Malaria - The Disease
- Press Releases
- EMVI Statutes
- Board Members and Scientific Advisory Committee Members
- Memoranda of Understanding and Intent
- EMVI Strategy
- Project Portfolio
- Polyprotein FP9 PP and MVA PP Phase Ia Oxford
- PfAMA1 Phase Ia Nijmegen
- PfAMA1 - DDB-TDA
- PfAMA1 - Second Generation
- PfAMA1 - Phase Ib Mali
- GMZ1 (PfGLURP) in the L lactis system
- GMZ2 Phase Ia Tübingen
- GMZ2 - DDA-TDB
- GMZ2 Phase Ib in adults Gabon (AMANET)
- GMZ2 Phase Ib in African children Gabon (AMANET)
- JAIVAC-1 Phase I in adults
- Var2-CSA DBL3-X and Var2CSA
- TBV - Pf48-45
- Completed Trials
- Annual Reports
- The Donors
- Mid-Term Review 2005
- Directives - Guidelines - Regulations
- Directives - Guidelines on Good Clinical Practice
- Directives - Guidelines on Good Manufacturing Practice
- Directives - Guidelines - Regulations on Clinical Trials
- Directives - Guidelines - Regulations on Medicinal Products
- Meeting Reports
- The Thematic Network Meeting, March 1999
- Long Synthetic Peptides in Malaria Vaccine Development, October 1999
- Clinical Trials Protocol, May 2000
- Clinical Testing of Pre-erythrocytic Malaria Vaccines, November 2000
- Combination Vaccines, January 2002
- Pregnancy Associated Malaria - on the brink, September 2003
- Experimental Infections in Humans, December 2003
- Phase II Workshop, September 2004
- Procedures
- Calls
- Vacancies